Tuberculosis Medicine Access: Why Equitable Supply Still Matters in 2025

Tuberculosis: Why Equitable Access Still Matters in 2025

Despite decades of progress, tuberculosis (TB) remains one of the world’s deadliest infectious diseases — affecting more than 10 million people every year, with over 1 million cases in children.

While TB is both preventable and curable, the story is far from over. Public hospitals and TB programs still face major barriers:

• Inconsistent availability of quality-assured TB medications

• Global shortages and cold-chain logistics challenges

• Risks of resistance due to ineffective or delayed treatments

• Disparities in access for remote, migrant, or high-risk populations

  
  

Our Commitment to Equitable Access

At Pro Pharmaceuticals Group, we believe access to essential TB medicines should not depend on geography, budget, or bureaucracy.

We actively work with:

• Public hospitals and state TB programs across Australia

• International NGOs and humanitarian organisations

• Licensed global suppliers aligned with WHO treatment protocols

…to ensure critical treatments reach the patients who need them, even when conventional supply chains fail.

Access with Accountability

We don’t just ship boxes. We support public health by:

• Offering non-profit, cost-recovery supply models for essential medicines

• Ensuring regulatory-compliant importation and distribution

• Maintaining ISO 9001-certified storage and validated cold chain practices

• Partnering only with suppliers that meet GMP, GDP, and ethical sourcing standards

As Australia and the global community continue to tackle TB in all its forms — drug-sensitive, MDR-TB, and XDR-TB — we remain committed to helping hospitals bridge the supply gap responsibly.

📌 Learn more about our ethical sourcing and global access work on our CSR page.

Tuberculosis Medicine Access: Why Equitable Supply Still Matters in 2025